Navigation Links
Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
Date:2/16/2010

l also receive, on a blinded basis, either intravenous placebo or intravenous REOLYSIN. All dosing takes place in the first five days of each cycle with all patients receiving standard intravenous doses of paclitaxel and carboplatin on day one only, and on days one through five, either intravenous placebo or intravenous REOLYSIN at a dose of 3x1010 TCID50. Patients may continue to receive the trial combination therapy for up to eight, 21-day cycles and, thereafter, blinded placebo or blinded REOLYSIN until the patient has progressive disease or meets other criteria for removal from the trial. Oncolytics intends to conduct the first stage of the trial at approximately 25 centres in the U.S., U.K., and Belgium.

The primary endpoint for the trial is overall survival (OS); secondary endpoints include progression free survival (PFS), objective response rate (complete response (CR) + partial response (PR)) and duration of response, and safety and tolerability of REOLYSIN when administered in combination with paclitaxel and carboplatin. The first stage of the trial is designed to enroll 80 patients. The second stage is adaptive, and is designed to enroll between 100 and 400 patients with the most probable statistical enrolment being 195 patients in this stage. This adaptive trial design allows frequent data evaluation to determine if the probability of reaching a statistically significant endpoint has been achieved.

The decision to pursue a Phase 3 trial in head and neck cancers was predicated on positive results seen in the Company's U.K. Phase 1 and Phase 2 combination REOLYSIN and paclitaxel/carboplatin clinical trials, as well as significant preclinical work demonstrating synergy in combination with taxane or platinum-based drugs. Updated results from the U.K. Phase 1/2 trial reported in November 2009 demonstrated an overall response rate (PR and CR) of 42% and a total clinical ben
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... SAN JOSE, California , January 15, 2014 ... conjugates for cancer, today announced the appointment of Thomas C ... has over 20 years, development experience gained in the biotechnology ... "I am delighted to welcome Tom at this ...
(Date:1/15/2014)... Houston, TX (PRWEB) January 15, 2014 ... Alzheimer’s disease, and about 1 in 3 seniors will ... ( source ). These jaw-dropping figures have shocked many ... function and, hopefully, help prevent these tragic age-related cognitive ...
(Date:1/15/2014)... January 15, 2014 2013 was a ... Brain State Technologies®. They saw continued independent research led ... who were awarded a $1 million grant from the ... “Brain and Behavior” a peer reviewed journal, Amy Grant ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. ... Road, Warrington, Pa. , Details: The Hepatitis B ... a cure for hepatitis B and improving the quality of ... Ball on Friday, April 11 at Warrington Country Club in ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2
... , BUDAPEST, Hungary, October 9 ... General of the Commission of,the European Communities approved the ... Consortium (CancerGrid) to,TargetEx. , "This ... in,Hungary - "and an appreciation of our scientific potential ...
... Accuray Incorporated (Nasdaq: ARAY ), a global leader ... Analyst Meeting in Chicago, Ill., on Monday, November 2, 2009 ... with the 51st Annual Meeting of the American Society for ... the presentation will be available online from the Investor Relations ...
... 8 Deloitte Recap LLC (Recap) has launched the ... Deloitte, a new subscription service that provides analytical tools ... strategy, financial, legal, tax and R&D professionals. Each product ... needs to offer the right business intelligence tools for ...
Cached Biology Technology:TargetEx Leads the European Cancer Research Consortium 2Accuray Incorporated to Host Investor and Analyst Meeting at ASTRO 2Deloitte Recap Launches New Series of Biopharmaceutical Business Intelligence Tools 2
(Date:4/23/2014)... used to read quickly. It involves visual searching ... and/ or sentences. Similarly to humans, biological systems ... genetic information. Genes that need to be read ... encoding message, the easier it will be to ... de Cincia (IGC, Portugal) and Centre for Molecular ...
(Date:4/22/2014)... There,s a new secret to get your child to behave ... , A new Cornell study published in Eating Behaviors ... they had to bite with their front teeth such as ... rowdier than when these foods had been cut. ... as aggressive toward other kids," said Brian Wansink, Professor and ...
(Date:4/22/2014)... interim director of the University of Montana,s Wildlife Biology Program, ... Proceedings of the National Academy of Sciences on how ... ... Survey, the University of Washington, the Cary Institute of Ecosystem ... Northern Research Station examined 664 water samples collected every 10 ...
Breaking Biology News(10 mins):Cell division speed influences gene architecture 2Biting vs. chewing 2New research focuses on streamwater chemistry, landscape variation 2
... a summit on managing extreme events held last month in ... and the Willis Research Network, part of Willis Group Holdings, ... pledged to continue exploring activities aimed at increasing the physical ... 2011 has been a notable year for the high human ...
... ALBANY, N.Y., Oct. 18, 2011 When North Carolina,s "Laura,s ... state became the 8th state in the last year to ... of DUI laws from penalizing cars to required—and enforced—sobriety for ... is poised to join the movement, as state lawmakers look ...
... KENYA (14 October 2011) On a continent battered by ... released today from the World Agroforestry Centre documents an ... poor farmers in Southern Africa are now significantly boosting ... and shrubs to naturally fertilize their fields. The ...
Cached Biology News:US science academy and global reinsurance broker spark 2US science academy and global reinsurance broker spark 3US science academy and global reinsurance broker spark 4Are Alcohol Anklets the New Ignition Interlock? 2Are Alcohol Anklets the New Ignition Interlock? 3Are Alcohol Anklets the New Ignition Interlock? 4400,000 farmers in southern Africa using 'fertilizer trees' to improve food security 2400,000 farmers in southern Africa using 'fertilizer trees' to improve food security 3
For the quantitative determination of canine Interleukin 10,(IL-10) concentrations in cell culture supernates, canine serum,and plasma....
RAT ANTI RAT RT1Au (CLASS I POLYMORPHIC) Immunogen: AO lymphoid cells...
Human VEGF R Phycoerythrin Sampler (Cl 89106, 49560, 54733)...
MOUSE ANTI SIMIAN VIRUS 5:FITC Immunogen: Simian virus 5...
Biology Products: